Future research using IRS2 inhibition in ex vivo studies, including a larger cohort of MPN patients, and in MPN animal models may help to predict the in vivo effectiveness and collateral effects of IRS2 inhibitors. The gene discussed is IRS2; the disease is myeloproliferative neoplasm.